# Colgate-Palmolive (CL) - Recent Events ## Filings that contain financial statements Each earnings 8-K below furnishes a press release (Exhibit 99) with condensed unaudited statements. These are not the audited or reviewed filings; the Form 10-Q and Form 10-K carry the full statements. - Form 8-K filed 2026-10-30, accession 0000021665-26-000047: third quarter 2026 results. Income statements for the three and nine months ended September 30, 2026 and 2025; balance sheets at September 30, 2026, December 31, 2025 and September 30, 2025; nine-month cash flow statements for 2026 and 2025; segment information and non-GAAP reconciliations. - Form 8-K filed 2026-07-31, accession 0000021665-26-000041: second quarter 2026 results (three and six months ended June 30, 2026 and 2025), with condensed income statements, balance sheets, six-month cash flows and segment tables. - Form 8-K filed 2026-05-01, accession 0000021665-26-000022: first quarter 2026 results (three months ended March 31, 2026 and 2025), with the same set of condensed statements. - Form 8-K filed 2026-03-17, accession 0000021665-26-000010: recast segment information (no consolidated statements) for 2025, 2024 and 2023 and for the 2025 interim periods, on the new segment structure. - Form 8-K filed 2026-01-30, accession 0000021665-26-000003: fourth quarter and full year 2025 results (year ended December 31, 2025 and 2024). ## Earnings and guidance - 2026-10-30 (0000021665-26-000047): Third quarter 2026 net sales were $5,369 million, up 4.6% from $5,131 million. Organic sales rose 3.6%, which includes a 0.2% drag from lower private label pet food sales. GAAP diluted EPS was $0.94 against $0.91, and Base Business (non-GAAP) EPS was $0.97, up 7%. GAAP gross margin was 60.2%, up 80 basis points. Net cash from operations was $2,913 million for the first nine months of 2026, against $2,745 million a year earlier. The company narrowed its sales guidance and raised gross margin and Base Business EPS guidance for full-year 2026: - Net sales are now expected up 4% to 5% (previously 2% to 6%). - Organic sales growth is now expected broadly in line with the nine-month performance (previously 1% to 4%). - GAAP and Base Business gross margin are now expected up (previously roughly flat). - Base Business EPS growth is now expected at 5% to 7% (previously mid-single-digit). - Advertising is still expected up in dollars and as a share of sales, and GAAP EPS is still expected to grow by double digits. - 2026-07-31 (0000021665-26-000041): Second quarter 2026 net sales rose 4.9% and organic sales rose 2.4%. GAAP EPS fell 5% to $0.86 and Base Business EPS rose 8% to $0.99. Guidance for sales and GAAP EPS was maintained. GAAP and Base Business gross margin guidance moved to roughly flat (previously down), and Base Business EPS growth to mid-single-digit (previously low- to mid-single-digit). - 2026-05-01 (0000021665-26-000022): First quarter 2026 net sales rose 8.4% and organic sales rose 2.9%. GAAP EPS fell 6% to $0.80 and Base Business EPS rose 7% to $0.97. Sales and EPS guidance was maintained. Gross margin guidance moved to down (previously up). - 2026-01-30 (0000021665-26-000003): Full-year 2025 net sales were $20,382 million, up 1.4%. GAAP EPS fell 25% to $2.63, reflecting the skin health impairment below. Base Business EPS rose 3% to $3.69, and operating cash flow was a record $4,198 million. Initial 2026 guidance was net sales up 2% to 6%, organic growth of 1% to 4%, gross margin expansion, and low to mid-single-digit Base Business EPS growth. - 2025-10-31 (0000021665-25-000052): Third quarter 2025 net sales rose 2.0%, organic sales rose 0.4%, and GAAP EPS was $0.91. The company updated its organic sales guidance for 2025 and maintained its EPS guidance. ## Impairment - Fourth quarter 2025, reported 2026-01-30 (0000021665-26-000003): the company took a non-cash, after-tax charge of $794 million to adjust the carrying values of goodwill and intangible assets of the skin health business. It cited lower than expected category growth and weaker performance, particularly in China, and lowered its outlook for the business, primarily Filorga. Goodwill on the balance sheet fell from $3,702 million at September 30, 2025 to $3,122 million at December 31, 2025 (0000021665-26-000047, Table 3). ## Restructuring: Strategic Growth and Productivity Program - 2025-07-31 (0000021665-25-000040): the Board approved a three-year productivity program with expected cumulative pre-tax charges of $200 to $300 million, substantially all incurred by December 31, 2028, recorded in the Corporate segment. - 2025-10-31 (0000021665-25-000052): the program was named the Strategic Growth and Productivity Program. Charges were estimated at 65% to 75% employee-related and 25% to 35% asset-related and other, with 75% to 85% resulting in cash. - 2026-05-01 (0000021665-26-000022): on April 30, 2026 the Board approved an expansion. Cumulative pre-tax charges are now estimated at $350 million to $550 million (previously $200 million to $300 million). The mix is 70% to 80% employee-related and 20% to 30% asset-related and other, with 80% to 90% in cash. Substantially all charges are still expected by December 31, 2028. By region the charges are North America 5% to 10%, Latin America 15% to 20%, Europe, Middle East & Africa 25% to 30%, Asia Pacific 10% to 15%, Hill's Pet Nutrition 10% to 15% and Corporate 20% to 25%. - The Form 10-Q for the quarter ended September 30, 2026 (accession 0000021665-26-000048) states that Corporate operating profit for the nine months included program charges of $327 million. ## Segment realignment - 2026-03-17 (0000021665-26-000010): effective for the quarter ended March 31, 2026, Colgate combined its Europe and Africa/Eurasia (excluding Russia and Belarus) segments and its Skin Health business (previously in North America) into a new Europe, Middle East & Africa segment. Russia and Belarus moved from Africa/Eurasia to Asia Pacific. Consolidated results were unchanged. The exhibit recasts segment sales and operating profit for 2023, 2024 and 2025 and for the 2025 interim periods. - Basis note: the Form 10-K for 2025 (accession 0000021665-26-000006) reports segments on the former structure. The Form 10-Q and the 2026 earnings releases use the new structure, and their 2025 comparatives are recast. Segment figures from the 2025 filings and 2026 filings should not be compared without the recast exhibit. As an example of the new basis, the recast 2025 full-year net sales were $4,276 million for Europe, Middle East & Africa and $3,679 million for North America. ## Capital actions - 2025-05-02 (0001104659-25-044105): $500 million of 4.200% Senior Notes due 2030 were issued on May 2, 2025 (underwriting agreement April 28, 2025). - 2025-11-10 (0001104659-25-109135): EUR 600 million of 3.250% Senior Notes due 2035 were issued on November 10, 2025 (underwriting agreement November 3, 2025). - Share repurchases and dividends: for the first nine months of 2026, purchases of treasury shares were $927 million (against $804 million in 2025) and dividends paid were $1,308 million (against $1,300 million), per the cash flow statement in 0000021665-26-000047. The 10-Q shows dividends of $0.53 per share in the third quarter of 2026, against $0.52. - Total debt was $7,716 million at September 30, 2026, against $7,988 million at December 31, 2025 (0000021665-26-000047, Table 3). ## M&A - No acquisition or divestiture 8-K appears in the period. The Form 10-Q (0000021665-26-000048, Note 4) describes a completed acquisition: on April 30, 2025 the company acquired Care TopCo Pty Ltd, owner of the Prime100 fresh pet food business in Australia, for cash consideration of AU$471 million ($301 million), financed with debt and cash. It is closed, and was disclosed in the 10-Q rather than in an 8-K. ## Management and board - 2025-05-29 (0000021665-25-000025): Shane Grant (formerly of Danone) was elected Chief Operating Officer, Americas, effective June 16, 2025. Prabha Parameswaran, Group President, Growth and Strategy, announced her retirement effective October 1, 2025 and became Vice Chair. Panagiotis Tsourapas and John Hazlin were promoted. - 2026-03-12 (0000021665-26-000008): Christopher S. Boerner (Chair and CEO of Bristol Myers Squibb) was elected to the Board effective March 15, 2026. Steven Cahillane, who became CEO of Kraft Heinz, said he would not stand for re-election in May 2026. - 2026-04-09 (0000021665-26-000015): Chief Legal Officer and Secretary Jennifer Daniels will retire in 2026. Betsy Fishbone becomes Chief Legal Officer and Secretary on June 1, 2026, and Ms. Daniels becomes Vice Chair. - 2026-05-13 (0000021665-26-000025): at the May 8, 2026 annual meeting, all ten nominees were elected, auditor PricewaterhouseCoopers was ratified, and the say-on-pay vote passed. Stockholder proposals on removing DEI from board candidate considerations and on an independent Board Chairman were not approved. A similar independent chairman proposal and a plastic packaging proposal also failed at the 2025 meeting (0000021665-25-000022).